|
|
|
| The Therapeutic Effect of the Induced Insulin Secreting Cells on Rat Diabetes |
| YUAN Feng-shan1, WANG Chang-jun2, DONG Fei1, ZHAO Yu-hang1 |
1. The First Affiliated Hospital, China Medical University, Shenyang 110001,China;
2. Health Bureau of Tieling City, Liaoning Province,Tieling 112000,China |
|
|
|
Abstract Objective: To observe the induction of differentiation and therapeutic effect of insulin secreting cells on rat diabetes. Methods: The bone marrow stem cells were extracted form rats and induced into insulin secreting cells with nicotinamide and exendin-4. 24 Wistar rats were randomized into normal, diabetes, and induction group. The diabetes model were established for the diabetes group and induction group. The induced cells were intraperitoneally injected into rats of the induction group. The weight, blood glucose ( fasting and OGTT 120min ), and fasting serum insulin were measured. At the end of the experiment, liver, spleen, pancreas were removed, and the double positive(insulin and BrdU) cells were calculated by immunohistochemistry. Results: At the end of administration, the fasting serum insulin of induction group was significant higher than the diabetes group (P<0.05), and the fasting and OGTT 120min blood glucose was lower than the diabetes group(P both<0.05). The ratio of insulin positive cells in the induction group was higher than diabetes group, and some insulin and BrdU duble-positive cells were found in pancreas, liver, and spleen of induction group. Conclusion: Nicotinamide and exendin-4 can induce bone marrow stem cells into insulin secreting cells, and these cells can increase the serum insulin, reduce the serum glucose, then improve the rat diabetes.
|
|
Received: 02 November 2010
Published: 27 May 2011
|
|
|
|
|
|
[1] Madec A M, Mallone R, Afonso G, et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia, 2009,52(7):1391-1399.
[2] 孙晓晖,王颜刚.干细胞移植定向分化为胰岛β细胞治疗糖尿病.中国组织工程研究与临床康复,2009,13(1):165-168. Sun X H, Wang Y G. Journal of Clinical Rehabilitative Tissue Engineering Research, 2009,13(1):165-168.
[3] 赵春华.干细胞原理、技术与临床应用.北京:化学工业出版社, 2006, 63-81. Zhao C H. Principle, Technology, and Clinic Application of Embryonic Cells. Beijing: Chemical Industry Press, 2006, 63-81.
[4] Choi K S, Shin J S, Lee J J, et al. In vitro trans-differentiation of rat mesenchymal cells into insulin-producing cells by rat pancreatic extract. Biochem Biophys Res Commun, 2005,330(4): 1299-1305.
[5] Da Silva M L, Chagastelles P C, Nardi N B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci, 2006,119(Pt 11):2204-2213.
[6] 刘伯轩,刘师伟,王建华,等.骨髓间充质干细胞移植后2型糖尿病鼠血糖及肾脏病变的改善.中国组织工程研究与临床康复,2009,13(10):1872-1876. Liu B X, Liu S W, Wang J H, et al. Journal of Clinical Rehabilitative Tissue Engineering Research, 2009,13(10):1872-1876.
[7] Tropel P, Nale D, Platet N. Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. Exp Cell Res, 2004,295(2):395-406.
[8] Bai L, Meredith G, Tuch B E. Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells. J Endocrinol, 2005, 186(2): 343-352.
[9] Guerci B, Martin C S. Exenatide: its position in the treatment of type 2 diabetes.Ann Endocrinol, 2008,69(3):201-209.
[10] Gao F, Wu D Q, Hu Y H, et al. In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. Transl Res, 2008,151(6):293-302.
[11] Yu B S, Wang A R. Glucagon-like peptide 1 based therapy for type 2 diabetes. World J Pediatr, 2008,4(1): 8-13.
[12] Gao F, Wu D Q, Hu Y H, et al. In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. Transl Res, 2008, 151(6):293-302.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
